Respiratory Virus Hospitalization Surveillance Network (RESP-NET) Content Implementation Guide, published by HL7 International / Public Health. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/fhir-resp-net-ig/ and changes regularly. See the Directory of published versions
| Official URL: http://hl7.org/fhir/us/resp-net/ValueSet/resp-net-labtest-covid-codes | Version: 2.0.0-ballot | |||
| Standards status: Informative | Computable Name: RESPNetCovidCodes | |||
| Other Identifiers: OID:2.16.840.1.113883.4.642.40.52.48.2 | ||||
Usage:Reporting: Triggering, Priority: Routine |
||||
Copyright/Legal: This material contains content from LOINC (http://loinc.org). LOINC is copyright © 1995-2020, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee and is available at no cost under the license at http://loinc.org/license. LOINC® is a registered United States trademark of Regenstrief Institute, Inc. Current Procedural Terminology (CPT) is copyright 2020 American Medical Association. All rights reserved |
||||
List of Covid test codes
References
This value set is not used here; it may be used elsewhere (e.g. specifications and/or implementations that use this content)
version: 1; Last updated: 2024-08-19 22:06:32+0000
Profile: US Public Health Triggering ValueSet
This value set includes codes based on the following rules:
http://loinc.org version Not Stated (use latest from terminology server)| Code | Display |
| 102048-6 | SARS coronavirus 2 & Respiratory syncytial virus Ag |
| 95941-1 | Influenza virus A & Influenza virus B & SARS coronavirus 2 & Respiratory syncytial virus RNA panel |
| 100861-4 | Cells.CD4+CD154+/Cells.CD4^after stimulation with SARS-CoV-2 Nucleocapsid peptide |
| 100858-0 | Cells.CD4+CD154+/Cells.CD4^after stimulation with SARS-CoV-2 Spike peptide |
| 100862-2 | Cells.CD4.Interferon gamma-expressing/Cells.CD4^after stimulation with SARS-CoV-2 Nucleocapsid peptide |
| 100859-8 | Cells.CD4.Interferon gamma-expressing/Cells.CD4^after stimulation with SARS-CoV-2 Spike peptide |
| 100863-0 | Cells.CD4.Tumor necrosis factor alfa-expressing/Cells.CD4^after stimulation with SARS-CoV-2 Nucleocapsid peptide |
| 100860-6 | Cells.CD4.Tumor necrosis factor alfa-expressing/Cells.CD4^after stimulation with SARS-CoV-2 Spike peptide |
| 95942-9 | Influenza virus A & Influenza virus B & SARS coronavirus+SARS coronavirus 2 Ag panel |
| 97099-6 | Influenza virus A & Influenza virus B & SARS coronavirus 2 Ag panel |
| 95941-1 | Influenza virus A & Influenza virus B & SARS coronavirus 2 & Respiratory syncytial virus RNA panel |
| 95380-2 | Influenza virus A & Influenza virus B & SARS coronavirus 2 & SARS-related coronavirus RNA panel |
| 95423-0 | Influenza virus A & Influenza virus B & SARS coronavirus 2 identified |
| 95422-2 | Influenza virus A & Influenza virus B & SARS coronavirus 2 RNA panel |
| 100345-8 | Influenza virus A & Influenza virus B & SARS coronavirus 2 RNA panel |
| 98733-9 | Percent neutralization by SARS coronavirus 2 spike protein RBD Ab.neut |
| 99771-8 | SARS coronavirus 2 spike & nucleocapsid protein stimulated gamma interferon panel |
| 98846-9 | SARS coronavirus 2 stimulated gamma interferon release by Helper (CD4+) T-cells^^corrected for background |
| 98847-7 | SARS coronavirus 2 stimulated gamma interferon release by lymphocytes^^corrected for background |
| 99774-2 | SARS coronavirus 2 stimulated gamma interferon release by T-cells.Nucleocapsid Ag spot count^^corrected for background |
| 99773-4 | SARS coronavirus 2 stimulated gamma interferon release by T-cells.Spike Ag spot count^^corrected for background |
| 95209-3 | SARS coronavirus+SARS coronavirus 2 Ag |
| 94763-0 | SARS coronavirus 2 |
| 94661-6 | SARS coronavirus 2 Ab |
| 95825-6 | SARS coronavirus 2 Ab |
| 98069-8 | SARS coronavirus 2 Ab |
| 94762-2 | SARS coronavirus 2 Ab |
| 95542-7 | SARS coronavirus 2 Ab |
| 94769-7 | SARS coronavirus 2 Ab |
| 96118-5 | SARS coronavirus 2 Ab panel |
| 94504-8 | SARS coronavirus 2 Ab panel |
| 94503-0 | SARS coronavirus 2 Ab panel |
| 94558-4 | SARS coronavirus 2 Ag |
| 96119-3 | SARS coronavirus 2 Ag |
| 97097-0 | SARS coronavirus 2 Ag |
| 96094-8 | SARS coronavirus 2 & SARS-related coronavirus RNA panel |
| 98080-5 | SARS coronavirus 2 & SARS-related coronavirus RNA panel |
| 96896-6 | SARS coronavirus 2 clade |
| 96764-6 | SARS coronavirus 2 E gene |
| 96763-8 | SARS coronavirus 2 E gene |
| 94562-6 | SARS coronavirus 2 Ab.IgA |
| 94768-9 | SARS coronavirus 2 Ab.IgA |
| 95427-1 | SARS coronavirus 2 Ab.IgA |
| 94720-0 | SARS coronavirus 2 Ab.IgA |
| 95125-1 | SARS coronavirus 2 Ab.IgA+IgM |
| 96742-2 | SARS coronavirus 2 Ab.IgG |
| 94761-4 | SARS coronavirus 2 Ab.IgG |
| 94563-4 | SARS coronavirus 2 Ab.IgG |
| 94507-1 | SARS coronavirus 2 Ab.IgG |
| 95429-7 | SARS coronavirus 2 Ab.IgG |
| 94505-5 | SARS coronavirus 2 Ab.IgG |
| 94547-7 | SARS coronavirus 2 Ab.IgG+IgM |
| 95416-4 | SARS coronavirus 2 Ab.IgM |
| 94564-2 | SARS coronavirus 2 Ab.IgM |
| 94508-9 | SARS coronavirus 2 Ab.IgM |
| 95428-9 | SARS coronavirus 2 Ab.IgM |
| 94506-3 | SARS coronavirus 2 Ab.IgM |
| 96895-8 | SARS coronavirus 2 lineage |
| 100157-7 | SARS coronavirus 2 lineage |
| 96957-6 | SARS coronavirus 2 M gene |
| 103557-5 | SARS coronavirus 2 Mpro gene mutation detected |
| 95521-1 | SARS coronavirus 2 N gene |
| 96898-2 | SARS coronavirus 2 N gene |
| 94510-5 | SARS coronavirus 2 N gene |
| 94311-8 | SARS coronavirus 2 N gene |
| 94312-6 | SARS coronavirus 2 N gene |
| 95522-9 | SARS coronavirus 2 N gene |
| 94760-6 | SARS coronavirus 2 N gene |
| 96986-5 | SARS coronavirus 2 N gene |
| 95409-9 | SARS coronavirus 2 N gene |
| 94533-7 | SARS coronavirus 2 N gene |
| 94756-4 | SARS coronavirus 2 N gene |
| 94757-2 | SARS coronavirus 2 N gene |
| 95425-5 | SARS coronavirus 2 N gene |
| 96448-6 | SARS coronavirus 2 N gene |
| 96958-4 | SARS coronavirus 2 N gene |
| 94766-3 | SARS coronavirus 2 N gene |
| 94316-7 | SARS coronavirus 2 N gene |
| 94307-6 | SARS coronavirus 2 N gene |
| 94308-4 | SARS coronavirus 2 N gene |
| 99596-9 | SARS coronavirus 2 nucleocapsid protein Ab.IgG |
| 95411-5 | SARS coronavirus 2 Ab.neut |
| 95410-7 | SARS coronavirus 2 Ab.neut |
| 97098-8 | SARS coronavirus 2 Nsp2 gene |
| 98132-4 | SARS coronavirus 2 ORF1a region |
| 98494-8 | SARS coronavirus 2 ORF1a region |
| 96899-0 | SARS coronavirus 2 ORF1ab region |
| 94644-2 | SARS coronavirus 2 ORF1ab region |
| 94511-3 | SARS coronavirus 2 ORF1ab region |
| 94559-2 | SARS coronavirus 2 ORF1ab region |
| 95824-9 | SARS coronavirus 2 ORF1ab region |
| 94639-2 | SARS coronavirus 2 ORF1ab region |
| 97104-4 | SARS coronavirus 2 ORF1ab region |
| 98131-6 | SARS coronavirus 2 ORF1b region |
| 98493-0 | SARS coronavirus 2 ORF1b region |
| 94646-7 | SARS coronavirus 2 RdRp gene |
| 94645-9 | SARS coronavirus 2 RdRp gene |
| 96120-1 | SARS coronavirus 2 RdRp gene |
| 94534-5 | SARS coronavirus 2 RdRp gene |
| 96091-4 | SARS coronavirus 2 RdRp gene |
| 94314-2 | SARS coronavirus 2 RdRp gene |
| 96123-5 | SARS coronavirus 2 RdRp gene |
| 99314-7 | SARS coronavirus 2 RdRp gene mutation detected |
| 94745-7 | SARS coronavirus 2 RNA |
| 94746-5 | SARS coronavirus 2 RNA |
| 94819-0 | SARS coronavirus 2 RNA |
| 94565-9 | SARS coronavirus 2 RNA |
| 94759-8 | SARS coronavirus 2 RNA |
| 95406-5 | SARS coronavirus 2 RNA |
| 96797-6 | SARS coronavirus 2 RNA |
| 95608-6 | SARS coronavirus 2 RNA |
| 94500-6 | SARS coronavirus 2 RNA |
| 95424-8 | SARS coronavirus 2 RNA |
| 94845-5 | SARS coronavirus 2 RNA |
| 94822-4 | SARS coronavirus 2 RNA |
| 94660-8 | SARS coronavirus 2 RNA |
| 94309-2 | SARS coronavirus 2 RNA |
| 96829-7 | SARS coronavirus 2 RNA |
| 96897-4 | SARS coronavirus 2 RNA panel |
| 94531-1 | SARS coronavirus 2 RNA panel |
| 95826-4 | SARS coronavirus 2 RNA panel |
| 94306-8 | SARS coronavirus 2 RNA panel |
| 96900-6 | SARS coronavirus 2 S gene |
| 94642-6 | SARS coronavirus 2 S gene |
| 94643-4 | SARS coronavirus 2 S gene |
| 94640-0 | SARS coronavirus 2 S gene |
| 95609-4 | SARS coronavirus 2 S gene |
| 96765-3 | SARS coronavirus 2 S gene |
| 94767-1 | SARS coronavirus 2 S gene |
| 94641-8 | SARS coronavirus 2 S gene |
| 96752-1 | SARS coronavirus 2 S gene mutation |
| 96751-3 | SARS coronavirus 2 S gene mutation detected |
| 99597-7 | SARS coronavirus 2 spike protein Ab.IgG |
| 96603-6 | SARS coronavirus 2 spike protein RBD Ab.neut |
| 98732-1 | SARS coronavirus 2 spike protein RBD Ab.neut |
| 98734-7 | SARS coronavirus 2 spike protein RBD Ab.neut |
| 96894-1 | SARS coronavirus 2 sequencing & identification panel |
| 95970-0 | SARS coronavirus 2 specific TCRB gene rearrangements |
| 100156-9 | SARS coronavirus 2 variant |
| 96741-4 | SARS coronavirus 2 variant |
| 96755-4 | SARS coronavirus 2 variant interpretation |
| 94764-8 | SARS coronavirus 2 whole genome |
| 99772-6 | SARS coronavirus 2 stimulated gamma interferon |
| 95971-8 | SARS coronavirus 2 stimulated gamma interferon |
| 95974-2 | SARS coronavirus 2 stimulated gamma interferon panel |
| 95972-6 | SARS coronavirus 2 stimulated gamma interferon release by T-cells^^corrected for background |
| 95973-4 | SARS coronavirus 2 stimulated gamma interferon release by T-cells |
| 94509-7 | SARS-related coronavirus E gene |
| 96121-9 | SARS-related coronavirus E gene |
| 94758-0 | SARS-related coronavirus E gene |
| 95823-1 | SARS-related coronavirus E gene |
| 94765-5 | SARS-related coronavirus E gene |
| 94315-9 | SARS-related coronavirus E gene |
| 96122-7 | SARS-related coronavirus E gene |
| 94313-4 | SARS-related coronavirus N gene |
| 94310-0 | SARS-related coronavirus N gene |
| 94502-2 | SARS-related coronavirus RNA |
| 94647-5 | SARS-related coronavirus RNA |
| 94532-9 | SARS-related coronavirus+MERS coronavirus RNA |
| 100342-5 | Volatile Organic Compounds associated with SARS-CoV-2 infection |
| 100972-9 | Influenza virus A and Influenza virus B and SARS coronavirus 2 RNA panel - Nose by NAA with non-probe detection |
http://www.ama-assn.org/go/cpt version Not Stated (use latest from terminology server)
| Code | Display |
| 87637 | Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique |
| 87631 | Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when perfor |
| 87632 | Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when perfor |
| 87633 | Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when perfor |
| 87635 | Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique |
| 87636 | Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique |
| 0241U | Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B, respiratory syncytial virus [RSV]), upper respiratory specimen, each pathogen |
| 87635 | Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique |
| 87636 | Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique |
| 87637 | Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique |
| 86328 | Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single step method (eg, reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) |
| 86408 | Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]); screen |
| 86409 | Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]); titer |
| 86413 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) antibody, quantitative |
| 87811 | Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) |
| 0224U | Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), includes titer(s), when performed |
| 0226U | Surrogate viral neutralization test (sVNT), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), ELISA, plasma, serum |
| 0202U | Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen rep |
| 0223U | Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen rep |
| 0225U | Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for |
| 87913 | Infectious agent genotype analysis by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), mutation identification in targeted region(s) |
| 0240U | Detection of SARS-CoV-2, Influenza A and Influenza B |
| 87426 | Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute resp |
| 87428 | Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute resp |
| 86318 | Immunoassay for infectious agent antibody(ies) and to be a parent to 86328 |
| 87252 | Viral Culture, General; Virus isolation; tissue culture inoculation, observation, and presumptive identification by cytopathic effect |
Expansion from tx.fhir.org based on:
This value set contains 183 concepts
| System | Code | Display (en) | status | JSON | XML |
http://loinc.org | 102048-6 | SARS coronavirus 2 and Respiratory syncytial virus Ag [Presence] in Nasopharynx by Immunofluorescence | |||
http://loinc.org | 95941-1 | Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection | |||
http://loinc.org | 100861-4 | Cells.CD4+CD154+/CD4 cells in Blood --after stimulation with SARS-CoV-2 Nucleocapsid peptide | TRIAL | ||
http://loinc.org | 100858-0 | Cells.CD4+CD154+/CD4 cells in Blood --after stimulation with SARS-CoV-2 Spike peptide | TRIAL | ||
http://loinc.org | 100862-2 | Cells.CD4.Interferon gamma-expressing/CD4 cells in Blood --after stimulation with SARS-CoV-2 Nucleocapsid peptide | TRIAL | ||
http://loinc.org | 100859-8 | Cells.CD4.Interferon gamma-expressing/CD4 cells in Blood --after stimulation with SARS-CoV-2 Spike peptide | TRIAL | ||
http://loinc.org | 100863-0 | Cells.CD4.Tumor necrosis factor alfa-expressing/CD4 cells in Blood --after stimulation with SARS-CoV-2 Nucleocapsid peptide | TRIAL | ||
http://loinc.org | 100860-6 | Cells.CD4.Tumor necrosis factor alfa-expressing/CD4 cells in Blood --after stimulation with SARS-CoV-2 Spike peptide | TRIAL | ||
http://loinc.org | 95942-9 | Influenza virus A and B and SARS-CoV+SARS-CoV-2 (COVID-19) Ag panel - Upper respiratory specimen by Rapid immunoassay | |||
http://loinc.org | 97099-6 | Influenza virus A and B and SARS-CoV-2 (COVID-19) Ag panel - Upper respiratory specimen by Rapid immunoassay | |||
http://loinc.org | 95380-2 | Influenza virus A and B and SARS-CoV-2 (COVID-19) and SARS-related CoV RNA panel - Respiratory system specimen by NAA with probe detection | |||
http://loinc.org | 95423-0 | Influenza virus A and B and SARS-CoV-2 (COVID-19) identified in Respiratory system specimen by NAA with probe detection | |||
http://loinc.org | 95422-2 | Influenza virus A and B and SARS-CoV-2 (COVID-19) RNA panel - Respiratory system specimen by NAA with probe detection | |||
http://loinc.org | 100345-8 | Influenza virus A and B and SARS-CoV-2 (COVID-19) RNA panel - Specimen by NAA with probe detection | |||
http://loinc.org | 98733-9 | Percent neutralization by SARS coronavirus 2 spike protein RBD neutralizing antibody in Serum or Plasma by Immunoassay | |||
http://loinc.org | 99771-8 | SARS coronavirus 2 spike and nucleocapsid protein stimulated gamma interferon panel - Blood | |||
http://loinc.org | 98846-9 | SARS coronavirus 2 stimulated gamma interferon release by Helper (CD4+) T-cells [Units/volume] corrected for background in Blood by Immunoassay | |||
http://loinc.org | 98847-7 | SARS coronavirus 2 stimulated gamma interferon release by lymphocytes [Units/volume] corrected for background in Blood by Immunoassay | |||
http://loinc.org | 99774-2 | SARS coronavirus 2 stimulated gamma interferon release by T-cells.Nucleocapsid Ag spot count [#] corrected for background in Blood | |||
http://loinc.org | 99773-4 | SARS coronavirus 2 stimulated gamma interferon release by T-cells.Spike Ag spot count [#] corrected for background in Blood | |||
http://loinc.org | 95209-3 | SARS-CoV+SARS-CoV-2 (COVID-19) Ag [Presence] in Respiratory system specimen by Rapid immunoassay | |||
http://loinc.org | 94763-0 | SARS-CoV-2 (COVID-19) [Presence] in Specimen by Organism specific culture | |||
http://loinc.org | 94661-6 | SARS-CoV-2 (COVID-19) Ab [Interpretation] in Serum or Plasma | |||
http://loinc.org | 95825-6 | SARS-CoV-2 (COVID-19) Ab [Presence] in DBS by Immunoassay | |||
http://loinc.org | 98069-8 | SARS-CoV-2 (COVID-19) Ab [Presence] in Saliva (oral fluid) by Rapid immunoassay | |||
http://loinc.org | 94762-2 | SARS-CoV-2 (COVID-19) Ab [Presence] in Serum or Plasma by Immunoassay | |||
http://loinc.org | 95542-7 | SARS-CoV-2 (COVID-19) Ab [Presence] in Serum, Plasma or Blood by Rapid immunoassay | |||
http://loinc.org | 94769-7 | SARS-CoV-2 (COVID-19) Ab [Units/volume] in Serum or Plasma by Immunoassay | |||
http://loinc.org | 96118-5 | SARS-CoV-2 (COVID-19) Ab panel - DBS by Immunoassay | |||
http://loinc.org | 94504-8 | SARS-CoV-2 (COVID-19) Ab panel - Serum or Plasma by Immunoassay | |||
http://loinc.org | 94503-0 | SARS-CoV-2 (COVID-19) Ab panel - Serum, Plasma or Blood by Rapid immunoassay | |||
http://loinc.org | 94558-4 | SARS-CoV-2 (COVID-19) Ag [Presence] in Respiratory system specimen by Rapid immunoassay | |||
http://loinc.org | 96119-3 | SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Immunoassay | |||
http://loinc.org | 97097-0 | SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Rapid immunoassay | |||
http://loinc.org | 96094-8 | SARS-CoV-2 (COVID-19) and SARS-related CoV RNA panel - Respiratory system specimen by NAA with probe detection | |||
http://loinc.org | 98080-5 | SARS-CoV-2 (COVID-19) and SARS-related CoV RNA panel - Saliva (oral fluid) by NAA with probe detection | |||
http://loinc.org | 96896-6 | SARS-CoV-2 (COVID-19) clade [Type] in Specimen by Molecular genetics method | |||
http://loinc.org | 96764-6 | SARS-CoV-2 (COVID-19) E gene [Cycle Threshold #] in Respiratory system specimen by NAA with probe detection | |||
http://loinc.org | 96763-8 | SARS-CoV-2 (COVID-19) E gene [Presence] in Respiratory system specimen by NAA with probe detection | |||
http://loinc.org | 94562-6 | SARS-CoV-2 (COVID-19) IgA Ab [Presence] in Serum or Plasma by Immunoassay | |||
http://loinc.org | 94768-9 | SARS-CoV-2 (COVID-19) IgA Ab [Presence] in Serum, Plasma or Blood by Rapid immunoassay | |||
http://loinc.org | 95427-1 | SARS-CoV-2 (COVID-19) IgA Ab [Titer] in Serum or Plasma by Immunofluorescence | |||
http://loinc.org | 94720-0 | SARS-CoV-2 (COVID-19) IgA Ab [Units/volume] in Serum or Plasma by Immunoassay | |||
http://loinc.org | 95125-1 | SARS-CoV-2 (COVID-19) IgA+IgM [Presence] in Serum or Plasma by Immunoassay | |||
http://loinc.org | 96742-2 | SARS-CoV-2 (COVID-19) IgG Ab [Mass/volume] in Serum or Plasma by Immunoassay | |||
http://loinc.org | 94761-4 | SARS-CoV-2 (COVID-19) IgG Ab [Presence] in DBS by Immunoassay | |||
http://loinc.org | 94563-4 | SARS-CoV-2 (COVID-19) IgG Ab [Presence] in Serum or Plasma by Immunoassay | |||
http://loinc.org | 94507-1 | SARS-CoV-2 (COVID-19) IgG Ab [Presence] in Serum, Plasma or Blood by Rapid immunoassay | |||
http://loinc.org | 95429-7 | SARS-CoV-2 (COVID-19) IgG Ab [Titer] in Serum or Plasma by Immunofluorescence | |||
http://loinc.org | 94505-5 | SARS-CoV-2 (COVID-19) IgG Ab [Units/volume] in Serum or Plasma by Immunoassay | |||
http://loinc.org | 94547-7 | SARS-CoV-2 (COVID-19) IgG+IgM Ab [Presence] in Serum or Plasma by Immunoassay | |||
http://loinc.org | 95416-4 | SARS-CoV-2 (COVID-19) IgM Ab [Presence] in DBS by Immunoassay | |||
http://loinc.org | 94564-2 | SARS-CoV-2 (COVID-19) IgM Ab [Presence] in Serum or Plasma by Immunoassay | |||
http://loinc.org | 94508-9 | SARS-CoV-2 (COVID-19) IgM Ab [Presence] in Serum, Plasma or Blood by Rapid immunoassay | |||
http://loinc.org | 95428-9 | SARS-CoV-2 (COVID-19) IgM Ab [Titer] in Serum or Plasma by Immunofluorescence | |||
http://loinc.org | 94506-3 | SARS-CoV-2 (COVID-19) IgM Ab [Units/volume] in Serum or Plasma by Immunoassay | |||
http://loinc.org | 96895-8 | SARS-CoV-2 (COVID-19) lineage [Identifier] in Specimen by Molecular genetics method | |||
http://loinc.org | 100157-7 | SARS-CoV-2 (COVID-19) lineage [Type] in Specimen by Sequencing | |||
http://loinc.org | 96957-6 | SARS-CoV-2 (COVID-19) M gene [Presence] in Upper respiratory specimen by NAA with probe detection | |||
http://loinc.org | 103557-5 | SARS-CoV-2 (COVID-19) Mpro gene mutation detected [Identifier] in Specimen by Molecular genetics method Nominal | |||
http://loinc.org | 95521-1 | SARS-CoV-2 (COVID-19) N gene [#/volume] (viral load) in Respiratory system specimen by NAA with probe detection | |||
http://loinc.org | 96898-2 | SARS-CoV-2 (COVID-19) N gene [Cycle Threshold #] in Oropharyngeal wash by NAA with probe detection | |||
http://loinc.org | 94510-5 | SARS-CoV-2 (COVID-19) N gene [Cycle Threshold #] in Specimen by NAA with probe detection | |||
http://loinc.org | 94311-8 | SARS-CoV-2 (COVID-19) N gene [Cycle Threshold #] in Specimen by Nucleic acid amplification using CDC primer-probe set N1 | |||
http://loinc.org | 94312-6 | SARS-CoV-2 (COVID-19) N gene [Cycle Threshold #] in Specimen by Nucleic acid amplification using CDC primer-probe set N2 | |||
http://loinc.org | 95522-9 | SARS-CoV-2 (COVID-19) N gene [Log #/volume] (viral load) in Respiratory system specimen by NAA with probe detection | |||
http://loinc.org | 94760-6 | SARS-CoV-2 (COVID-19) N gene [Presence] in Nasopharynx by NAA with probe detection | |||
http://loinc.org | 96986-5 | SARS-CoV-2 (COVID-19) N gene [Presence] in Nose by NAA with non-probe detection | |||
http://loinc.org | 95409-9 | SARS-CoV-2 (COVID-19) N gene [Presence] in Nose by NAA with probe detection | |||
http://loinc.org | 94533-7 | SARS-CoV-2 (COVID-19) N gene [Presence] in Respiratory system specimen by NAA with probe detection | |||
http://loinc.org | 94756-4 | SARS-CoV-2 (COVID-19) N gene [Presence] in Respiratory system specimen by Nucleic acid amplification using CDC primer-probe set N1 | |||
http://loinc.org | 94757-2 | SARS-CoV-2 (COVID-19) N gene [Presence] in Respiratory system specimen by Nucleic acid amplification using CDC primer-probe set N2 | |||
http://loinc.org | 95425-5 | SARS-CoV-2 (COVID-19) N gene [Presence] in Saliva (oral fluid) by NAA with probe detection | |||
http://loinc.org | 96448-6 | SARS-CoV-2 (COVID-19) N gene [Presence] in Saliva (oral fluid) by Nucleic acid amplification using CDC primer-probe set N1 | |||
http://loinc.org | 96958-4 | SARS-CoV-2 (COVID-19) N gene [Presence] in Saliva (oral fluid) by Nucleic acid amplification using CDC primer-probe set N2 | |||
http://loinc.org | 94766-3 | SARS-CoV-2 (COVID-19) N gene [Presence] in Serum or Plasma by NAA with probe detection | |||
http://loinc.org | 94316-7 | SARS-CoV-2 (COVID-19) N gene [Presence] in Specimen by NAA with probe detection | |||
http://loinc.org | 94307-6 | SARS-CoV-2 (COVID-19) N gene [Presence] in Specimen by Nucleic acid amplification using CDC primer-probe set N1 | |||
http://loinc.org | 94308-4 | SARS-CoV-2 (COVID-19) N gene [Presence] in Specimen by Nucleic acid amplification using CDC primer-probe set N2 | |||
http://loinc.org | 99596-9 | SARS-CoV-2 (COVID-19) N protein IgG Ab [Presence] in Serum or Plasma by Immunoassay | |||
http://loinc.org | 95411-5 | SARS-CoV-2 (COVID-19) neutralizing antibody [Presence] in Serum by pVNT | |||
http://loinc.org | 95410-7 | SARS-CoV-2 (COVID-19) neutralizing antibody [Titer] in Serum by pVNT | |||
http://loinc.org | 97098-8 | SARS-CoV-2 (COVID-19) Nsp2 gene [Presence] in Upper respiratory specimen by NAA with probe detection | |||
http://loinc.org | 98132-4 | SARS-CoV-2 (COVID-19) ORF1a region [Presence] in Respiratory system specimen by NAA with probe detection | |||
http://loinc.org | 98494-8 | SARS-CoV-2 (COVID-19) ORF1a region [Presence] in Saliva (oral fluid) by NAA with probe detection | |||
http://loinc.org | 96899-0 | SARS-CoV-2 (COVID-19) ORF1ab region [Cycle Threshold #] in Oropharyngeal wash by NAA with probe detection | |||
http://loinc.org | 94644-2 | SARS-CoV-2 (COVID-19) ORF1ab region [Cycle Threshold #] in Respiratory system specimen by NAA with probe detection | |||
http://loinc.org | 94511-3 | SARS-CoV-2 (COVID-19) ORF1ab region [Cycle Threshold #] in Specimen by NAA with probe detection | |||
http://loinc.org | 94559-2 | SARS-CoV-2 (COVID-19) ORF1ab region [Presence] in Respiratory system specimen by NAA with probe detection | |||
http://loinc.org | 95824-9 | SARS-CoV-2 (COVID-19) ORF1ab region [Presence] in Saliva (oral fluid) by NAA with probe detection | |||
http://loinc.org | 94639-2 | SARS-CoV-2 (COVID-19) ORF1ab region [Presence] in Specimen by NAA with probe detection | |||
http://loinc.org | 97104-4 | SARS-CoV-2 (COVID-19) ORF1ab region [Units/volume] (viral load) in Upper respiratory specimen by NAA with probe detection | |||
http://loinc.org | 98131-6 | SARS-CoV-2 (COVID-19) ORF1b region [Presence] in Respiratory system specimen by NAA with probe detection | |||
http://loinc.org | 98493-0 | SARS-CoV-2 (COVID-19) ORF1b region [Presence] in Saliva (oral fluid) by NAA with probe detection | |||
http://loinc.org | 94646-7 | SARS-CoV-2 (COVID-19) RdRp gene [Cycle Threshold #] in Respiratory system specimen by NAA with probe detection | |||
http://loinc.org | 94645-9 | SARS-CoV-2 (COVID-19) RdRp gene [Cycle Threshold #] in Specimen by NAA with probe detection | |||
http://loinc.org | 96120-1 | SARS-CoV-2 (COVID-19) RdRp gene [Presence] in Lower respiratory specimen by NAA with probe detection | |||
http://loinc.org | 94534-5 | SARS-CoV-2 (COVID-19) RdRp gene [Presence] in Respiratory system specimen by NAA with probe detection | |||
http://loinc.org | 96091-4 | SARS-CoV-2 (COVID-19) RdRp gene [Presence] in Saliva (oral fluid) by NAA with probe detection | |||
http://loinc.org | 94314-2 | SARS-CoV-2 (COVID-19) RdRp gene [Presence] in Specimen by NAA with probe detection | |||
http://loinc.org | 96123-5 | SARS-CoV-2 (COVID-19) RdRp gene [Presence] in Upper respiratory specimen by NAA with probe detection | |||
http://loinc.org | 99314-7 | SARS-CoV-2 (COVID-19) RdRp gene mutation detected [Identifier] in Specimen by Molecular genetics method | |||
http://loinc.org | 94745-7 | SARS-CoV-2 (COVID-19) RNA [Cycle Threshold #] in Respiratory system specimen by NAA with probe detection | |||
http://loinc.org | 94746-5 | SARS-CoV-2 (COVID-19) RNA [Cycle Threshold #] in Specimen by NAA with probe detection | |||
http://loinc.org | 94819-0 | SARS-CoV-2 (COVID-19) RNA [Log #/volume] (viral load) in Specimen by NAA with probe detection | |||
http://loinc.org | 94565-9 | SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with non-probe detection | |||
http://loinc.org | 94759-8 | SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection | |||
http://loinc.org | 95406-5 | SARS-CoV-2 (COVID-19) RNA [Presence] in Nose by NAA with probe detection | |||
http://loinc.org | 96797-6 | SARS-CoV-2 (COVID-19) RNA [Presence] in Oropharyngeal wash by NAA with probe detection | |||
http://loinc.org | 95608-6 | SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with non-probe detection | |||
http://loinc.org | 94500-6 | SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection | |||
http://loinc.org | 95424-8 | SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by Sequencing | |||
http://loinc.org | 94845-5 | SARS-CoV-2 (COVID-19) RNA [Presence] in Saliva (oral fluid) by NAA with probe detection | |||
http://loinc.org | 94822-4 | SARS-CoV-2 (COVID-19) RNA [Presence] in Saliva (oral fluid) by Sequencing | |||
http://loinc.org | 94660-8 | SARS-CoV-2 (COVID-19) RNA [Presence] in Serum or Plasma by NAA with probe detection | |||
http://loinc.org | 94309-2 | SARS-CoV-2 (COVID-19) RNA [Presence] in Specimen by NAA with probe detection | |||
http://loinc.org | 96829-7 | SARS-CoV-2 (COVID-19) RNA [Presence] in Specimen from Donor by NAA with probe detection | |||
http://loinc.org | 96897-4 | SARS-CoV-2 (COVID-19) RNA panel - Oropharyngeal wash by NAA with probe detection | |||
http://loinc.org | 94531-1 | SARS-CoV-2 (COVID-19) RNA panel - Respiratory system specimen by NAA with probe detection | |||
http://loinc.org | 95826-4 | SARS-CoV-2 (COVID-19) RNA panel - Saliva (oral fluid) by NAA with probe detection | |||
http://loinc.org | 94306-8 | SARS-CoV-2 (COVID-19) RNA panel - Specimen by NAA with probe detection | |||
http://loinc.org | 96900-6 | SARS-CoV-2 (COVID-19) S gene [Cycle Threshold #] in Oropharyngeal wash by NAA with probe detection | |||
http://loinc.org | 94642-6 | SARS-CoV-2 (COVID-19) S gene [Cycle Threshold #] in Respiratory system specimen by NAA with probe detection | |||
http://loinc.org | 94643-4 | SARS-CoV-2 (COVID-19) S gene [Cycle Threshold #] in Specimen by NAA with probe detection | |||
http://loinc.org | 94640-0 | SARS-CoV-2 (COVID-19) S gene [Presence] in Respiratory system specimen by NAA with probe detection | |||
http://loinc.org | 95609-4 | SARS-CoV-2 (COVID-19) S gene [Presence] in Respiratory system specimen by Sequencing | |||
http://loinc.org | 96765-3 | SARS-CoV-2 (COVID-19) S gene [Presence] in Saliva (oral fluid) by NAA with probe detection | |||
http://loinc.org | 94767-1 | SARS-CoV-2 (COVID-19) S gene [Presence] in Serum or Plasma by NAA with probe detection | |||
http://loinc.org | 94641-8 | SARS-CoV-2 (COVID-19) S gene [Presence] in Specimen by NAA with probe detection | |||
http://loinc.org | 96752-1 | SARS-CoV-2 (COVID-19) S gene mutation [Presence] in Specimen by Molecular genetics method | |||
http://loinc.org | 96751-3 | SARS-CoV-2 (COVID-19) S gene mutation detected [Identifier] in Specimen by Molecular genetics method | |||
http://loinc.org | 99597-7 | SARS-CoV-2 (COVID-19) S protein IgG Ab [Presence] in Serum or Plasma by Immunoassay | |||
http://loinc.org | 96603-6 | SARS-CoV-2 (COVID-19) S protein RBD neutralizing antibody [Presence] in Serum or Plasma by sVNT | |||
http://loinc.org | 98732-1 | SARS-CoV-2 (COVID-19) S protein RBD neutralizing antibody [Titer] in Serum or Plasma by Immunoassay | |||
http://loinc.org | 98734-7 | SARS-CoV-2 (COVID-19) S protein RBD neutralizing antibody [Units/volume] in Serum or Plasma by Immunoassay | |||
http://loinc.org | 96894-1 | SARS-CoV-2 (COVID-19) sequencing and identification panel - Specimen by Molecular genetics method | |||
http://loinc.org | 95970-0 | SARS-CoV-2 (COVID-19) specific TCRB gene rearrangements [Presence] in Blood by Sequencing | |||
http://loinc.org | 100156-9 | SARS-CoV-2 (COVID-19) variant [Type] in Specimen by NAA with probe detection | |||
http://loinc.org | 96741-4 | SARS-CoV-2 (COVID-19) variant [Type] in Specimen by Sequencing | |||
http://loinc.org | 96755-4 | SARS-CoV-2 (COVID-19) variant interpretation in Specimen Narrative | |||
http://loinc.org | 94764-8 | SARS-CoV-2 (COVID-19) whole genome [Nucleotide sequence] in Isolate or Specimen by Sequencing | |||
http://loinc.org | 99772-6 | SARS-CoV-2 stimulated gamma interferon [Interpretation] in Blood Qualitative | |||
http://loinc.org | 95971-8 | SARS-CoV-2 stimulated gamma interferon [Presence] in Blood | |||
http://loinc.org | 95974-2 | SARS-CoV-2 stimulated gamma interferon panel - Blood | |||
http://loinc.org | 95972-6 | SARS-CoV-2 stimulated gamma interferon release by T-cells [Units/volume] corrected for background in Blood | |||
http://loinc.org | 95973-4 | SARS-CoV-2 stimulated gamma interferon release by T-cells [Units/volume] in Blood | |||
http://loinc.org | 94509-7 | SARS-related coronavirus E gene [Cycle Threshold #] in Specimen by NAA with probe detection | |||
http://loinc.org | 96121-9 | SARS-related coronavirus E gene [Presence] in Lower respiratory specimen by NAA with probe detection | |||
http://loinc.org | 94758-0 | SARS-related coronavirus E gene [Presence] in Respiratory system specimen by NAA with probe detection | |||
http://loinc.org | 95823-1 | SARS-related coronavirus E gene [Presence] in Saliva (oral fluid) by NAA with probe detection | |||
http://loinc.org | 94765-5 | SARS-related coronavirus E gene [Presence] in Serum or Plasma by NAA with probe detection | |||
http://loinc.org | 94315-9 | SARS-related coronavirus E gene [Presence] in Specimen by NAA with probe detection | |||
http://loinc.org | 96122-7 | SARS-related coronavirus E gene [Presence] in Upper respiratory specimen by NAA with probe detection | |||
http://loinc.org | 94313-4 | SARS-related coronavirus N gene [Cycle Threshold #] in Specimen by Nucleic acid amplification using CDC primer-probe set N3 | |||
http://loinc.org | 94310-0 | SARS-related coronavirus N gene [Presence] in Specimen by Nucleic acid amplification using CDC primer-probe set N3 | |||
http://loinc.org | 94502-2 | SARS-related coronavirus RNA [Presence] in Respiratory system specimen by NAA with probe detection | |||
http://loinc.org | 94647-5 | SARS-related coronavirus RNA [Presence] in Specimen by NAA with probe detection | |||
http://loinc.org | 94532-9 | SARS-related coronavirus+MERS coronavirus RNA [Presence] in Respiratory system specimen by NAA with probe detection | |||
http://loinc.org | 100342-5 | Volatile Organic Compounds associated with SARS-CoV-2 infection [Presence] in Exhaled gas by Gas chromatography-mass spectrometry | |||
http://loinc.org | 100972-9 | Influenza virus A and Influenza virus B and SARS coronavirus 2 RNA panel - Nose by NAA with non-probe detection | |||
http://www.ama-assn.org/go/cpt | 87637 | Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique | |||
http://www.ama-assn.org/go/cpt | 87631 | Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 3-5 targets | |||
http://www.ama-assn.org/go/cpt | 87632 | Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 6-11 targets | |||
http://www.ama-assn.org/go/cpt | 87633 | Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets | |||
http://www.ama-assn.org/go/cpt | 87635 | Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique | |||
http://www.ama-assn.org/go/cpt | 87636 | Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique | |||
http://www.ama-assn.org/go/cpt | 0241U | Respiratory infectious agent detection by RNA for severe acute respiratory syndrome coronavirus 2 (COVID 19), influenza A, influenza B, and respiratory syncytial virus, upper respiratory specimen, each reported as detected or not detected | |||
http://www.ama-assn.org/go/cpt | 86328 | Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single-step method (eg, reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) | |||
http://www.ama-assn.org/go/cpt | 86408 | Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]); screen | |||
http://www.ama-assn.org/go/cpt | 86409 | Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]); titer | |||
http://www.ama-assn.org/go/cpt | 86413 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) antibody, quantitative | |||
http://www.ama-assn.org/go/cpt | 87811 | Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) | |||
http://www.ama-assn.org/go/cpt | 0224U | Measurement of antibody to severe acute respiratory syndrome coronavirus 2 (COVID-19) | |||
http://www.ama-assn.org/go/cpt | 0226U | Surrogate viral neutralization test (sVNT) for detection of antibodies to severe acute respiratory syndrome coronavirus 2 (Covid-19) by | |||
http://www.ama-assn.org/go/cpt | 0202U | Test for detection of respiratory disease-causing organisms from back of nose and throat (nasopharynx) specimen, 22 target organisms including severe acute respiratory syndrome coronavirus 2 | |||
http://www.ama-assn.org/go/cpt | 0223U | Test for detection of respiratory disease-causing organisms from back of nose and throat (nasopharynx) specimen, 22 target organisms including severe acute respiratory syndrome coronavirus 2 | |||
http://www.ama-assn.org/go/cpt | 0225U | Test for detection of respiratory disease-causing organisms, 21 target organisms including severe acute respiratory syndrome coronavirus 2 (COVID-19) | |||
http://www.ama-assn.org/go/cpt | 87913 | Infectious agent genotype analysis by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), mutation identification in targeted region(s) | |||
http://www.ama-assn.org/go/cpt | 0240U | Respiratory infectious agent detection by RNA for severe acute respiratory syndrome coronavirus 2 (COVID-19), influenza A, and influenza B) in upper respiratory specimen, each reported as detected or not detected | |||
http://www.ama-assn.org/go/cpt | 87426 | Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) | |||
http://www.ama-assn.org/go/cpt | 87428 | Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B | |||
http://www.ama-assn.org/go/cpt | 86318 | Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single-step method (eg, reagent strip); | |||
http://www.ama-assn.org/go/cpt | 87252 | Virus isolation; tissue culture inoculation, observation, and presumptive identification by cytopathic effect |
Explanation of the columns that may appear on this page:
| Level | A few code lists that FHIR defines are hierarchical - each code is assigned a level. In this scheme, some codes are under other codes, and imply that the code they are under also applies |
| System | The source of the definition of the code (when the value set draws in codes defined elsewhere) |
| Code | The code (used as the code in the resource instance) |
| Display | The display (used in the display element of a Coding). If there is no display, implementers should not simply display the code, but map the concept into their application |
| Definition | An explanation of the meaning of the concept |
| Comments | Additional notes about how to use the code |